Today: 7 February 2026
Subscribe
Browse Category

Healthcare News 11 December 2025 - 25 December 2025

Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms

Abbott Laboratories (ABT) News and Stock Outlook on Dec. 25, 2025: FDA Clears Volt PFA, FreeStyle Libre Alert Persists, Exact Sciences Deal Looms

Dec. 25, 2025 — Abbott Laboratories (NYSE: ABT) heads into the year-end stretch with a rare mix of near-term product momentum and headline-level risk management. Over the past several weeks—culminating in key December announcements—Abbott has (1) secured U.S. FDA approval for a next-generation atrial fibrillation ablation platform, (2) expanded its push into consumer biowearables, (3) navigated an FDA early alert tied to certain FreeStyle Libre sensors, and (4) doubled down on its diagnostics ambitions with a planned ~$23 billion enterprise-value acquisition of Exact Sciences. With U.S. markets closed for Christmas Day, investors are largely assessing Abbott based on its most
25 December 2025
·····
Healthcare Stocks Outlook (Dec. 25, 2025): Wegovy Pill Breakthrough, FDA Approvals, and a New Wave of M&A Heading Into 2026

Healthcare Stocks Outlook (Dec. 25, 2025): Wegovy Pill Breakthrough, FDA Approvals, and a New Wave of M&A Heading Into 2026

December 25, 2025 — U.S. markets are closed for Christmas, but healthcare stocks are ending the year with a burst of sector-defining catalysts: a landmark oral GLP‑1 approval for weight loss, multiple FDA green lights that moved biotech names sharply, and a renewed M&A drumbeat as big pharma and rare-disease specialists shop for growth. Below is a detailed, news-driven roundup of the most important healthcare stock headlines, forecasts, and analyst themes investors are digesting as of Dec. 25, 2025—and what they could mean for pharma stocks, biotech stocks, medtech stocks, and health insurance stocks in early 2026. Why healthcare stocks
25 December 2025
····
UnitedHealth Group (UNH) Stock News, Forecasts and Analysis for Dec. 22, 2025: Independent Reviews, DOJ Scrutiny, and 2026 Guidance in Focus

UnitedHealth Group (UNH) Stock News, Forecasts and Analysis for Dec. 22, 2025: Independent Reviews, DOJ Scrutiny, and 2026 Guidance in Focus

December 22, 2025 — UnitedHealth Group Incorporated (NYSE: UNH) is ending the year with investors focused less on “normal” quarterly momentum and more on a three-part storyline that could shape how the market values the healthcare giant in 2026: (1) management’s operational overhaul after independent reviews, (2) a heavy regulatory and legal backdrop, and (3) the next earnings call—when the company will finally lay out full-year 2026 guidance. As of Dec. 22, UNH shares were trading around $325 in U.S. trading, leaving the stock well below its highs and keeping UnitedHealth near the top of the list of “show-me” large
22 December 2025
·····
UnitedHealth (UNH) Stock: Key Audit Updates, DOJ Risks, Earnings Outlook and Analyst Forecasts Before the Market Opens Dec. 22, 2025

UnitedHealth (UNH) Stock: Key Audit Updates, DOJ Risks, Earnings Outlook and Analyst Forecasts Before the Market Opens Dec. 22, 2025

UnitedHealth Group Incorporated (NYSE: UNH) heads into the Monday, Dec. 22, 2025 U.S. market open with investors balancing a fresh company-led audit update against a busy regulatory and legal backdrop spanning Medicare Advantage, Optum Rx, and ongoing litigation. Friday’s close also sets the tone: UNH ended the last regular session at $327.42 after trading between roughly $326 and $335, with about 10.6 million shares changing hands. Yahoo Finance This is also a holiday-shortened stretch for markets. NYSE and Nasdaq are scheduled to close early on Wednesday, Dec. 24, and be closed on Thursday, Dec. 25 (Christmas Day)—conditions that can thin
22 December 2025
·····
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements, renewed focus on insurance premiums, and a fresh run of deal and IPO headlines that are reshaping investor expectations for 2026. Reuters+3Reuters+3Reuters+3 Below is a comprehensive roundup of the most market-moving healthcare news, plus the latest forecasts and sector analysis shaping how investors are positioning across pharma, biotech, managed care, medtech, and healthcare services into 2026. 1) Drug pricing is
20 December 2025
············
Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

Johnson & Johnson Stock (JNJ) Today: FDA Priority Voucher, Talc Verdict, Earnings Date and 2026 Growth Outlook

December 16, 2025 — Johnson & Johnson stock (NYSE: JNJ) is trading lower on Tuesday after pushing to fresh highs earlier this week, as investors weigh a mix of pipeline momentum, legal headlines, and an approaching earnings update that could clarify the company’s 2026 trajectory. StockAnalysis+1 Below is what’s moving Johnson & Johnson shares right now, what Wall Street is forecasting, and the key dates JNJ stock watchers have on the calendar. JNJ stock price check: what’s happening on Dec. 16, 2025 As of late morning U.S. time on December 16, JNJ stock was trading around the $211–$212 area, down
16 December 2025
·····
Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook

Merck Stock (MRK) News Today: BofA Raises Target to $120 as Winrevair Expansion and Dividend Date Spotlight 2026 Outlook

December 15, 2025 — Merck & Co., Inc. (NYSE: MRK) traded around $99.59 in Monday afternoon action, down about 0.23% on the day, as investors balanced a fresh wave of bullish analyst updates against a busy set of catalysts spanning Winrevair, Keytruda, vaccines, and headline regulatory scrutiny. The setup for MRK stock into year-end is increasingly about “what comes after Keytruda,” and the story is getting more layered: an expanded European pathway for Winrevair (sotatercept), a higher dividend heading into the ex-dividend date, and new legal and policy crosswinds around Merck’s newer product rollouts and the U.S. vaccine environment. What’s
15 December 2025
·····
Abbott Laboratories (ABT) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Abbott Laboratories (ABT) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025

Abbott Laboratories (NYSE: ABT) heads into Monday’s session with investors weighing a busy set of headlines—ranging from a fresh dividend hike to a high-profile acquisition in cancer diagnostics, plus regulatory attention around certain FreeStyle Libre sensors. ABT closed Friday, Dec. 12 at $125.46, up 1.77%, marking a third straight day of gains, though it remains about 11% below its 52‑week high. MarketWatch Below is what market watchers are likely to focus on before the opening bell on Monday, Dec. 15, 2025. The quick snapshot investors are starting with This matters because Monday’s opening trade may reflect how investors rank the
15 December 2025
·····
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Updated: December 14, 2025Coverage window for this report: December 8–14, 2025 Wall Street heads into the week of Dec. 15, 2025 with U.S. healthcare and pharma mega-caps back in the spotlight—pulled by three powerful forces that all intensified in the last seven days: (1) the obesity-drug arms race, (2) Washington’s policy crosscurrents around insurance subsidies and PBM transparency, and (3) a faster-moving FDA that is simultaneously accelerating reviews and reopening safety scrutiny in sensitive pediatric categories. Reuters+3Reuters+3Reuters+3 The result is a “defensive sector” that doesn’t feel defensive at all right now. The Federal Reserve’s Dec. 9–10 meeting delivered another layer
14 December 2025
········
Canada Stock Market Today: TSX Slips After Record High as Tech Drops, Cannabis Rally Lifts Healthcare (Dec. 12, 2025)

Canada Stock Market Today: TSX Slips After Record High as Tech Drops, Cannabis Rally Lifts Healthcare (Dec. 12, 2025)

TORONTO (After the Bell, 4:30 p.m. ET) — Canada’s benchmark stock index ended Friday in the red after a choppy session that saw early strength in cannabis and mining shares give way to a broad tech-led pullback. The S&P/TSX Composite Index closed down 0.4% (133.34 points) at 31,527.39, easing back from Thursday’s record close and trimming what had been shaping up as a stronger finish to the week. TradingView The late-day drag came largely from the same force weighing on global markets: renewed skepticism around richly valued technology and AI-linked names. The dynamic was stark on the TSX, where a surge in health
12 December 2025
···
Molina Healthcare Stock (NYSE: MOH) News on Dec. 12, 2025: Rally Extends as ACA Subsidy Deadline, 2026 Outlook, and Analyst Forecasts Collide

Molina Healthcare Stock (NYSE: MOH) News on Dec. 12, 2025: Rally Extends as ACA Subsidy Deadline, 2026 Outlook, and Analyst Forecasts Collide

Molina Healthcare, Inc. (NYSE: MOH) stock was trading around $169.53 on Friday, Dec. 12, 2025, after opening near $168.36 and moving between $166.62 and $171.81 during the session, according to consolidated market data. The move caps a notable short-term rebound for a stock that has spent much of 2025 digesting a steep earnings reset tied to medical cost trend pressure—especially in the Affordable Care Act (ACA) Marketplace—alongside rising policy uncertainty heading into 2026. Below is what’s driving Molina Healthcare stock today (Dec. 12, 2025), what the company’s own preliminary 2026 earnings view implies, and what Wall Street forecasts are signaling
12 December 2025
····
UnitedHealth Group (UNH) Stock Outlook After the November 21 Rebound: Can the Healthcare Giant Regain Its Swagger in 2026?

UnitedHealth Group (UNH) Stock Outlook After the November 21 Rebound: Can the Healthcare Giant Regain Its Swagger in 2026?

UnitedHealth Group Incorporated (NYSE: UNH) has been at the center of one of 2025’s biggest blue‑chip storylines: a brutal share-price collapse, a messy reset in Medicare Advantage, a Department of Justice (DOJ) probe, credit‑rating downgrades, and now a tentative turn toward recovery. Since November 21, 2025, a fresh wave of news, forecasts, and opinion pieces has reshaped how investors view UNH stock. Below is a structured, Google‑News‑friendly rundown of what’s happened from November 21, 2025 through today (December 11, 2025), what Wall Street expects for 2026, and what risks still hang over the story. UNH Stock Snapshot as of December
11 December 2025
·····
1 … 6 7 8 9 10 … 13

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
Go toTop